Codexis Inc (CDXS) - Debt to Equity

Corporate emblem and logo of Codexis, Inc. (CDXS)

Codexis, Inc. (CDXS) dominates the development of custom proteins for medicine and nutrition, leveraging its AI system and extensive patent portfolio. This price trend chart shows that the total debt-to-equity ratio is 2.36. The business relies on CodeEvolver to help partners optimize costs. A network of global carriers ensures supply stability, eliminating disruptions in the delivery of critical biocomponents.

CDXS: Codexis Inc Total Debt to Capital 07/04/2022 - 10/27/2026
Product sample of Codexis

The total debt-to-equity ratio measures the proportion of borrowed funds in the financing structure relative to the company's own resources. Low values for this metric indicate high financial autonomy and resilience to market shocks. By analyzing the total debt/equity chart, an investor can see the current leverage level, which for Codexis, Inc. (CDXS) is 2.36. This ratio confirms the company's balanced debt load, ensuring full coverage of operating expenses and investment costs through stable cash flows.

Analysis of competing companies

Total Debt to Capital tempus.com (TEM)|Debt to Equity Ratio QGEN|Debt to Equity Ionis Pharma IONS|Debt to Equity Ratio Repligen Inc. (RGEN)|Total Debt to Capital RNA (Avidity Biosciences)|Total Debt to Capital crisprtx.com CRSP|WGS: Total Debt to Capital|RARE: Total Debt to Equity Ratio|Debt to Equity BEAM|Sarepta Corp (SRPT) - Debt to Capital|Total Debt to Capital Twist Bioscience (TWST)|Debt to Equity Ratio 10xgenomics.com|Intellia Therapeutics, Inc. - Total Debt to Capital|Debt to Capital Stoke Therapeutics Inc STOK|BLFS - Total Debt to Equity Ratio|Debt to Equity Ratio Wave Pharma WVE|Total Debt to Capital MAZE (Maze Therapeutics Inc)|SION: Total Debt to Capital Coefficient|Prime Medicine - Debt to Equity|Total Debt to Capital Coefficient Taysha Gene Therapies Inc|QURE - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio MeiraGTx Corp|RGNX (REGENXBIO Inc.) - Total Debt to Capital|Total Debt to Capital Coefficient SLDB (solidbio.com)|OCGN - Debt to Equity|Debt to Equity Ratio Pacific Biosciences of California, Inc. PACB|BNTC: Total Debt to Capital|Design Corp (DSGN) - Total Debt to Equity Ratio|Rocket Pharmaceuticals - Total Debt to Equity Ratio|4dmoleculartherapeutics.com (FDMT) - Total Debt to Capital Coefficient|Total Debt to Capital LXEO|Total Debt to Equity Ratio Korro Bio, Inc|Total Debt to Capital Editas EDIT|Debt to Equity Ratio Silence Therapeutics Corp SLN|PRQR - Total Debt to Equity Ratio|sangamo.com - Debt to Equity Ratio|Debt to Equity NAUT (Nautilus Biotechnology Inc)|MGX - Total Debt to Capital Coefficient|Total Debt to Capital Precision BioSciences, Inc.|GBIO (Generation Bio) - Debt to Equity Ratio|Debt to Equity Boundless Bio, Inc. (BOLD)|Debt to Equity Ratio Exicure Corp|Total Debt to Capital IMNN|Total Debt to Capital phiopharma.com (PHIO)|Mustang Bio - Total Debt to Capital|TransCode Therapeutics Inc. - Total Debt to Equity Ratio|BNGO (Bionano) - Debt to Equity|APDN - Debt to Capital|Total Debt to Capital bluebird bio|ImmunoPrecise Antibodies Ltd. (IPA) - Debt to Equity Ratio|Total Debt to Capital OMGA (Omega)|Debt to Capital Singular Genomics Corp (OMIC)|Total Debt to Equity Ratio Regulus Therapeutics RGLS|Debt to Equity Ratio syros.com (SYRS)|Total Debt to Capital TBIO|TRACON Pharmaceuticals Inc. - Total Debt to Capital Coefficient|Debt to Equity UBX (Unity Bio)